JAMA Network Home
Sign In
Viewpoint

Gaps in US Psychedelic Policy and How to Close Them

JAMA Health Forum 10.1001/jamahealthforum.2025.4928

November 07, 2025 at 11:00 AM EST

Read the full article

This Viewpoint discusses how to fill policy gaps surrounding the use of psychedelics to treat mental health and substance use conditions, should they be approved by the US Food and Drug Administration.

Corresponding Author: Caleigh Propes, BA, Johns Hopkins Berman Institute of Bioethics, 1809 Ashland Ave, Baltimore, MD 21205 (cpropes1@jh.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2025.4928?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=110725

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks